FDA not rash in approving Nuvigil
Executive Summary
Cephalon's Nuvigil (armodafinil) approved June 15 for excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome, narcolepsy and shift-work sleep disorder. Approved labeling includes a bolded warning that a "serious rash requiring hospitalization and discontinuation of treatment" has been reported in patients using the product. The bolded warning adds that Nuvigil is not approved for use by children for any indication. A similar warning will be added to labeling for Cephalon's first-generation product Provigil (modafinil). Nuvigil had received an "approvable" letter in April 2006, with FDA requesting data on rashes in patients taking another modafinil-containing drug, Sparlon (1"The Pink Sheet" Aug. 21, 2006, p. 7)...
You may also be interested in...
FDA Rejects Sparlon Due To Single SJS Case; An Ominous Sign For Pharma?
FDA's decision that Cephalon's attention deficit hyperactivity disorder treatment Sparlon is not approvable - based on an adverse event in a single patient - could be indicative of a more challenging regulatory environment for manufacturers
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.